BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36068461)

  • 1. Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.
    Talebi Z; Sparreboom A; Colace SI
    Methods Mol Biol; 2022; 2547():63-94. PubMed ID: 36068461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic testing in oncology: a Brazilian perspective.
    Suarez-Kurtz G
    Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e565s. PubMed ID: 30328952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
    Diasio RB; Johnson MR
    Pharmacology; 2000 Sep; 61(3):199-203. PubMed ID: 10971206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
    Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
    Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.
    Chang WC; Tanoshima R; Ross CJD; Carleton BC
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():65-84. PubMed ID: 33006916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting.
    Luczak TS; Schillo PJ; Renier CM; Waring SC; Friday BB
    J Oncol Pharm Pract; 2022 Jun; 28(4):842-849. PubMed ID: 33853470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer pharmacogenetics.
    Marsh S; McLeod HL
    Br J Cancer; 2004 Jan; 90(1):8-11. PubMed ID: 14710198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deliberations about clinical pharmacogenetic testing in pediatric oncology.
    Issa AM; Aboushawareb SA; Eisenstat DD; Guilcher GM; Liu G; Rassekh SR; Strahlendorf C; Tallen G; Tanoshima R; Carleton B
    Per Med; 2021 Jul; 18(4):399-405. PubMed ID: 33973801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A stepwise approach to implementing pharmacogenetic testing in the primary care setting.
    Weitzel KW; Duong BQ; Arwood MJ; Owusu-Obeng A; Abul-Husn NS; Bernhardt BA; Decker B; Denny JC; Dietrich E; Gums J; Madden EB; Pollin TI; Wu RR; Haga SB; Horowitz CR
    Pharmacogenomics; 2019 Oct; 20(15):1103-1112. PubMed ID: 31588877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
    O'Donnell PH; Ratain MJ
    Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
    Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics and Personalized Medicine.
    Cecchin E; Stocco G
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
    Nagy M; Attya M; Patrinos GP
    Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy.
    Fujita K; Sasaki Y
    Curr Drug Metab; 2007 Aug; 8(6):554-62. PubMed ID: 17691917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
    Vassy JL; Stone A; Callaghan JT; Mendes M; Meyer LJ; Pratt VM; Przygodzki RM; Scheuner MT; Wang-Rodriguez J; Schichman SA;
    Genet Med; 2019 Feb; 21(2):382-390. PubMed ID: 29858578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implementation of pharmacogenetics.
    García-González X; Cabaleiro T; Herrero MJ; McLeod H; López-Fernández LA
    Drug Metab Pers Ther; 2016 Mar; 31(1):9-16. PubMed ID: 26751902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving Role of Pharmacogenetic Biomarkers to Predict Drug-Induced Hematological Disorders.
    Pattanaik S; Jain A; Ahluwalia J
    Ther Drug Monit; 2021 Apr; 43(2):201-220. PubMed ID: 33235023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies.
    Pozdeyev N; Yoo M; Mackie R; Schweppe RE; Tan AC; Haugen BR
    Oncotarget; 2016 Aug; 7(32):51619-51625. PubMed ID: 27322211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacogenetics: how do we ensure a favorable future for patients?
    Wiltshire T; Dong OM
    Pharmacogenomics; 2018 Apr; 19(6):553-562. PubMed ID: 29620450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.